Summary

The global dysmenorrhea treatment market, valued at approximately USD 5,937.8 million in 2022, is projected to reach USD 6,324.5 million in 2023 and USD 13,106.5 million by 2032, exhibiting a CAGR of 8.3% over the forecast period 2023-2033. Dysmenorrhea, characterized by severe menstrual cramps, predominantly affects women from adolescence. The pain originates due to prostaglandins produced in the uterine lining, which cause muscular spasms. A variety of underlying conditions may also lead to menstrual problems.
Increasing occurrences of dysmenorrhea due to lifestyle modifications, environmental changes, and dietary preferences have escalated health consciousness among women, driving the demand for treatment options. The rising consumer awareness regarding dysmenorrhea therapies and the affordability of over-the-counter medications further bolster market growth. Moreover, the growing reliance on pain relief drugs during menstruation significantly contributes to market expansion.
Technological advancements within the healthcare sector are anticipated to fuel market growth throughout the forecast period. However, potential side effects associated with long-term treatments, high morbidity of menstrual cramps, inadequate treatments, and traditional family values could impede market progress. Nonetheless, the introduction of portable and advanced DMAs for on-site analysis is expected to enhance global market adoption.
Regionally, North America dominated the market in 2022 with a 37.2% share and is expected to maintain its lead through 2033, driven by technological innovations, increased healthcare spending, and the presence of key industry players. Other regions, particularly Asia-Pacific and EMEA, are anticipated to exhibit significant growth due to rapid industrialization, expanding manufacturing sectors, and substantial investments in research and development within the healthcare industry.
Major market players included in this report are:
Pfizer Inc.
Bayer AG
Johnson & Johnson Services, Inc.
Novartis AG
Abbott Laboratories
Merck & Co., Inc.
Sanofi S.A.
GlaxoSmithKline plc
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Zydus Cadila
Boehringer Ingelheim International GmbH
Ferring Pharmaceuticals
Endo Pharmaceuticals Inc.
Allergan plc
The detailed segments and sub-segment of the market are explained below:
By Diseases:
• Primary Dysmenorrhea
• Secondary Dysmenorrhea
• Endometriosis
• Adenomyosis
• Uterine Myomas
• Endometrial Polyps
• Cervical Stenosis
• Obstructive Malformations of Genital Tract
By Therapeutic Class:
• Non-Hormonal Medical Treatment
o Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
 Non-Selective NSAIDS
 Cox-2 Inhibitors
o Transdermal Glyceryl Trinitrate
o Over-The-Counter (OTC) Medications
• Hormonal Medicine Treatment
o Combined Oral Contraceptive
o Progestin Regimens
o Levonorgestrel Intrauterine System (LN-IUS)
• Surgical Options
o Laparoscopy
o Hysterectomy
o Presacral Neurectomy
o Laparoscopic Uterosacral Nerve Ablation (LUNA)
o Intrauterine Device (IUD)
Common content for ‘Report Description’
By Region:
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Spain
o Italy
o ROE
• Asia Pacific
o China
o India
o Japan
o Australia
o South Korea
o RoAPAC
• Latin America
o Brazil
o Mexico
• Middle East & Africa
o Saudi Arabia
o South Africa
o RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Global Dysmenorrhea Treatment Market Executive Summary
1.1. Global Dysmenorrhea Treatment Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Diseases
1.3.2. By Therapeutic Class
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Dysmenorrhea Treatment Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Dysmenorrhea Treatment Market Dynamics
3.1. Market Drivers
3.1.1. Growing healthcare spending
3.1.2. Increasing consumer awareness and low-cost medications
3.1.3. Technological advancements
3.2. Market Challenges
3.2.1. Side effects of long-term treatments
3.2.2. High morbidity leading to inadequate treatments
3.2.3. Traditional family values
3.3. Market Opportunities
3.3.1. Introduction of portable and advanced DMAs
3.3.2. Government initiatives and aging population
3.3.3. Increased disposable income and urbanization

Chapter 4. Global Dysmenorrhea Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Dysmenorrhea Treatment Market Size & Forecasts by Diseases 2022-2032
5.1. Segment Dashboard
5.2. Global Dysmenorrhea Treatment Market: Diseases Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Primary Dysmenorrhea
5.2.2. Secondary Dysmenorrhea
5.2.3. Endometriosis
5.2.4. Adenomyosis
5.2.5. Uterine Myomas
5.2.6. Endometrial Polyps
5.2.7. Cervical Stenosis
5.2.8. Obstructive Malformations of Genital Tract

Chapter 6. Global Dysmenorrhea Treatment Market Size & Forecasts by Therapeutic Class 2022-2032
6.1. Segment Dashboard
6.2. Global Dysmenorrhea Treatment Market: Therapeutic Class Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Non-Hormonal Medical Treatment
6.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.2.1.1.1. Non-Selective NSAIDS
6.2.1.1.2. Cox-2 Inhibitors
6.2.1.2. Transdermal Glyceryl Trinitrate
6.2.1.3. Over-The-Counter (OTC) Medications
6.2.2. Hormonal Medicine Treatment
6.2.2.1. Combined Oral Contraceptive
6.2.2.2. Progestin Regimens
6.2.2.3. Levonorgestrel Intrauterine System (LN-IUS)
6.2.3. Surgical Options
6.2.3.1. Laparoscopy
6.2.3.2. Hysterectomy
6.2.3.3. Presacral Neurectomy
6.2.3.4. Laparoscopic Uterosacral Nerve Ablation (LUNA)
6.2.3.5. Intrauterine Device (IUD)

Chapter 7. Global Dysmenorrhea Treatment Market Size & Forecasts by Region 2022-2032
7.1. North America Dysmenorrhea Treatment Market
7.1.1. U.S. Dysmenorrhea Treatment Market
7.1.1.1. Diseases breakdown size & forecasts, 2022-2032
7.1.1.2. Therapeutic Class breakdown size & forecasts, 2022-2032
7.1.2. Canada Dysmenorrhea Treatment Market
7.2. Europe Dysmenorrhea Treatment Market
7.2.1. U.K. Dysmenorrhea Treatment Market
7.2.2. Germany Dysmenorrhea Treatment Market
7.2.3. France Dysmenorrhea Treatment Market
7.2.4. Spain Dysmenorrhea Treatment Market
7.2.5. Italy Dysmenorrhea Treatment Market
7.2.6. Rest of Europe Dysmenorrhea Treatment Market
7.3. Asia-Pacific Dysmenorrhea Treatment Market
7.3.1. China Dysmenorrhea Treatment Market
7.3.2. India Dysmenorrhea Treatment Market
7.3.3. Japan Dysmenorrhea Treatment Market
7.3.4. Australia Dysmenorrhea Treatment Market
7.3.5. South Korea Dysmenorrhea Treatment Market
7.3.6. Rest of Asia Pacific Dysmenorrhea Treatment Market
7.4. Latin America Dysmenorrhea Treatment Market
7.4.1. Brazil Dysmenorrhea Treatment Market
7.4.2. Mexico Dysmenorrhea Treatment Market
7.4.3. Rest of Latin America Dysmenorrhea Treatment Market
7.5. Middle East & Africa Dysmenorrhea Treatment Market
7.5.1. Saudi Arabia Dysmenorrhea Treatment Market
7.5.2. South Africa Dysmenorrhea Treatment Market
7.5.3. Rest of Middle East & Africa Dysmenorrhea Treatment Market

Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Pfizer Inc.
8.1.2. Bayer AG
8.1.3. Johnson & Johnson Services, Inc.
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Pfizer Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Bayer AG
8.3.3. Johnson & Johnson Services, Inc.
8.3.4. Novartis AG
8.3.5. Abbott Laboratories
8.3.6. Merck & Co., Inc.
8.3.7. Sanofi S.A.
8.3.8. GlaxoSmithKline plc
8.3.9. Mylan N.V.
8.3.10. Teva Pharmaceutical Industries Ltd.
8.3.11. Zydus Cadila
8.3.12. Boehringer Ingelheim International GmbH
8.3.13. Ferring Pharmaceuticals
8.3.14. Endo Pharmaceuticals Inc.
8.3.15. Allergan plc

Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes